Ganetespib (STA-9090)

Catalog No.S1159

Ganetespib (STA-9090) Chemical Structure

Molecular Weight(MW): 364.4

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

Size Price Stock Quantity  
In DMSO USD 302 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • Loss of viability (Z score) resulting from HSP90 inhibition (HSP90i; ganetespib, 5 nM) in FANCA null GM6914 cells transduced with retroviruses encoding FANCA wild-type (squares; WT) or empty vector control (circles; null) in the presence (black symbols) of MMC (31.6 nM) or DMSO control (gray symbols). Data from three independent experiments are presented as mean ± SEM.

    Cell, 2017, 168(5):856-866. Ganetespib (STA-9090) purchased from Selleck.

    Breast cancer (MDA-MB-231), pancreatic cancer (PaTu2), lung cancer (A549), colon cancer HCT-116, and acute myeloid leukemia (SKM1) cell lines were incubated with increasing amounts of PU-H71 and STA-9090 as indicated. Western blot analysis with PRKD2, cleaved PARP, and cleaved caspase-9 antibodies is depicted.

    Cancer Res 2014 10.1158/0008-5472.CAN-14-1017. Ganetespib (STA-9090) purchased from Selleck.

  • Western blot analysis of the expression of Brd4 and Hsp90 from whole-cell lysates of Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 at indicated concentrations for 24 h (B), and in Pkd1 null MEK cells and Pkd1 mutant PN24 cells treated with STA9090 (200 nM) at indicated time points (C).

    Hum Mol Genet, 2015, 10.1093/hmg/ddv136. Ganetespib (STA-9090) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Targets
HSP90 [1]
(OSA 8 cells)
4 nM
In vitro

The 50% inhibitory concentrations (IC50) for Ganetespib against malignant mast cell lines are 10-50 times lower than that for 17-AAG, indicating that triazolone class of HSP90 inhibitors likely exhibits greater potency than geldanamycin based inhibitors. [1] Ganetespib inhibits MG63 cell lines with IC50 of 43 nM. [1] Ganetespib binds to the ATP-binding domain at the N-terminus of Hsp90 and serves as a potent Hsp90 inhibitor by causing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2 and c-Met as well as Wilms' tumor 1. [2] Ganetespib, at low nanomolar concentrations, potently arrests cell proliferation and induces apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. Ganetespib exhibits potent cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors. [3] Ganetespib treatment rapidly caused the degradation of known Hsp90 client proteins, exhibits superior potency to the ansamycin inhibitor 17-AAG, and shows sustained activity even with short exposure times.[3] In anohter study, Ganetespib induces apoptosis of malignant canine mast cell lines. Ganetespib is active at significantly lower concentrations for C2 and BR canine malignant mast cells with IC50 of 19 and 4 nM, respectively, while 17-AAG inhibits C2 and BR canine malignant mast cells with IC50 of 958 and 44 nM, respectively. [4] Both the expression of WT and mutant Kit are downregulated by 100 nM Ganetespib after 24 hours in all lines treated including C2 and BMCMCs cells. However, no effects on PI3K or HSP90 expression are observed following treatment with Ganetespib.[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HL60 NXTmXJJZSXCxcITvd4l{KEG|c3H5 M1jufVMxNzhyL{G1NE8zPTBibl2= MV2yOE81QC95MjDo MWfpcoR2[2W|IHTvd4Uh\GWyZX7kZY51KGmwZIXjeIlwdiCxZjDhdI9xfG:|aYO= M{XkblI2QDh{NUWw
MV411 Mn3zRZBweHSxc3nzJGF{e2G7 NXLzRZNPOzBxOECvNVUxNzJ3MDDuUS=> MoXSNlQwPDhxN{KgbC=> M4T6dYlv\HWlZYOg[I9{\SCmZYDlcoRidnRiaX7keYN1cW:wIH;mJIFxd3C2b4Ppdy=> MYOyOVg5OjV3MB?=
MGC-803 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXLWWW97OC5zLUGwNFAhdk1? NWrLZ5dkPzJiaB?= M1v1bolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MnPnNlU2QTB6MEW=
SGC-7901 NVHLNnNvS2WubDDWbYFjcWyrdImgRZN{[Xl? NXTmWJE6OC5zLUGwNFAhdk1? MYC3NkBp MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NWHEUG84OjV3OUC4NFU>
MKN-28 M4m2WWNmdGxiVnnhZoltcXS7IFHzd4F6 NVe4flBYOC5zLUGwNFAhdk1? M1\3PFczKGh? NVXyVG5xcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NHTWV2UzPTV7MEiwOS=>
MGC-803 NWLBU256TnWwY4Tpc44hSXO|YYm= MmD6NE4yNTFyMECgcm0> M3jFZVI1KGh? MVvpcoR2[2W|IFeyM20h[2WubD3jfYNt\SCjcoLld5Q> NGLNdo8zPTV7MEiwOS=>
HCT-116 NETpXGpHfW6ldHnvckBCe3OjeR?= NE\HUXM2OG6P NGXCWHYzPCCq MnHDSG1UVw>? NYH5[|lkcW6mdXPl[EBIOC:JMTDhdpJme3R? M3G4TFI2OjFyN{m0
HT-29 Mo\DSpVv[3Srb36gRZN{[Xl? MlXIOVBvVQ>? M2PPXlI1KGh? M{Tsc2ROW09? MVzpcoR2[2WmIFewM2cyKGG{cnXzeC=> MWeyOVIyODd7NB?=
SCC25 NEjiOlVEgXSxeHnjbZR6KEG|c3H5 MYqxNE82OCCwTR?= MmD1NlQhcA>? MV;k[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= NWHjfG5EOjV{MEW0N|A>
FUDA MojER5l1d3irY3n0fUBCe3OjeR?= NFHVUIMyOC93MDDuUS=> MU[yOEBp MWTk[YNz\WG|ZYOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViZHXw[Y5l\W62bIm= MWSyOVIxPTR|MB?=
Detroit562 NG[2d4FEgXSxeHnjbZR6KEG|c3H5 MYixNE82OCCwTR?= NX7ZXpd3OjRiaB?= Mn\Y[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckBld3OnIHTldIVv\GWwdHz5 NVXqeFU3OjV{MEW0N|A>
CAL27 NUnOU|NIS3m2b4jpZ4l1gSCDc4PhfS=> NWfDV|V1OTBxNUCgcm0> NEjmTIQzPCCq M4nabYRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDk[ZBmdmSnboTsfS=> NHzLWYwzPTJyNUSzNC=>
DSH1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XjNGlEPTB;NjDuUS=> NIftOWUzPDd6NEizPS=>
SW-1710 NUHxelhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTZibl2= NF\0XnMzPDd6NEizPS=>
T24 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XMemlEPTB;NzDuUS=> MWiyOFc5PDh|OR?=
RT112 NVPXRnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTlibl2= MYqyOFc5PDh|OR?=
639-V NXLsUJlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;JRoV2UUN3ME2xNEBvVQ>? MmDhNlQ4QDR6M{m=
SCaBER MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3hfW11UUN3ME2xNEBvVQ>? M2LBZVI1Pzh2OEO5
BFTC NV7RdWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF5IH7N MnPTNlQ4QDR6M{m=
J82 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPYXnNKSzVyPUG4JI5O NF2y[HYzPDd6NEizPS=>
HT-1376 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nmcmlEPTB;MkGgcm0> MUGyOFc5PDh|OR?=
647-V NGLCOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UOZZKSzVyPUK3JI5O MX2yOFc5PDh|OR?=
UM-UC3 NFmzTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXBbY5jUUN3ME2zN{BvVQ>? M4i2flI1Pzh2OEO5
LB831-BLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\IXotRUUN3ME2zOEBvVQ>? MYCyOFc5PDh|OR?=
KU-19-19 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN4IH7N MVOyOFc5PDh|OR?=
35612 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTN6IH7N Ml7vNlQ4QDR6M{m=
5637 NIPXeGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7kTWM2OD12NDDuUS=> NHTmV|QzPDd6NEizPS=>
HT-1197 NFPE[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkiwTWM2OD13MzDuUS=> MV6yOFc5PDh|OR?=
MGH-U3 M1L4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjtNFJ3UUN3ME21N{BvVQ>? M{DOfVI1Pzh2OEO5
TCCSUP M4XjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TjXWlEPTB;MUSyJI5O NHvscFQzPDd6NEizPS=>
RT4 NEXPPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF5M{Ogcm0> NIXqUWYzPDd6NEizPS=>
SW780 NWfUOXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wc2lEPTB;M{S1NUBvVQ>? NFnBPYszPDd6NEizPS=>
RKO NFTHeVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fRPWlEPTB;NDDuUS=> MYKyOFY5Ojd2Nx?=
LS-411 N NWDabYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrHO3FwUUN3ME21JI5O Moi5NlQ3QDJ5NEe=
SW620 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\YTWM2OD16IH7N MUmyOFY5Ojd2Nx?=
HCT-15 M{jMcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRThibl2= MniwNlQ3QDJ5NEe=
HuTu-80 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlSwTWM2OD1zMzDuUS=> NWTUbWhpOjR4OEK3OFc>
HCT 116 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL3TWM2OD1zNDDuUS=> MlmyNlQ3QDJ5NEe=
COLO-205 NESzcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3PTWM2OD1zNDDuUS=> NX76XodDOjR4OEK3OFc>
NCI-H747 NE\rS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LSbGlEPTB;MUegcm0> MkHxNlQ3QDJ5NEe=
COLO-678 NGDv[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfZeY5IUUN3ME2yNUBvVQ>? NFTHfHkzPDZ6Mke0Oy=>
LoVo NHnneYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrFWpFKSzVyPUKyJI5O MWKyOFY5Ojd2Nx?=
LS-1034 NF7G[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7nelgxUUN3ME2zNUBvVQ>? NITxNpQzPDZ6Mke0Oy=>
SNU-C2B MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTR3IH7N M{nsS|I1Pjh{N{S3
LS-123 NXiwXlluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L4bWlEPTB;N{Ogcm0> M1j2VFI1Pjh{N{S3
SK-CO-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThzIH7N NHeyPGUzPDZ6Mke0Oy=>
HCC2998 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jCNWlEPTB;MUK4JI5O M2C4[|I1Pjh{N{S3
MDA-MB-231 MmLYSpVv[3Srb36gRZN{[Xl? NUXLbXVHOTByIH7N MVOzNEBucW5? M3;JdIlvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDITWYuOc7z NUfW[XR7OjR{NEiyOlU>
MDA-MB-435 NHr6WoNHfW6ldHnvckBCe3OjeR?= MnPnNVAxKG6P MYWzNEBucW5? MUjpcohq[mm2czDhZ4N2dXWuYYTpc44hd2ZiSFnGMVHPuQ>? NHrXUHUzPDJ2OEK2OS=>
BT-20  MkHnSpVv[3Srb36gRZN{[Xl? M{npRlExOC9{NUCgcm0> NFr1RZIzPCCq MUfy[ZN2dHSnZDDpckBiKGSxc3Wt[IVx\W6mZX70JIRme3SjYnnsbZpifGmxbjDv[kBGT0[ULDDJS2YuUVJuIF3FWEwh[W6mIFPSRWY> NX;Fc2Z5OjRzN{O1OFE>
MDA-MB-231 NXLwT5lZTnWwY4Tpc44hSXO|YYm= NYT5SXNvOTByIH7N MUSyOEBp M13LeYlvcGmkaYTzJJRp\SCvaXfyZZRwenliYX7kJIlvfmG|aY\lJINieGGlaYT5xsA> MX[yOFE4OzV2MR?=
H82 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP5d4FKSzVyPUOwMlI4KG6P NVT4UVVzOjRzNk[1NFU>
GLC4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmwTWM2OD1{MD60O{BvVQ>? MUWyOFE3PjVyNR?=
H69 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K5cWlEPTB;OEOuN|Yhdk1? MUSyOFE3PjVyNR?=
H128 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvQfXFKSzVyPU[5MlU2KG6P M1HnSlI1OTZ4NUC1
H146 NVPzOoFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\tTWM2OD1{OD61NUBvVQ>? MnfoNlQyPjZ3MEW=
H187 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfr[2lMUUN3ME2yOE46QSCwTR?= NInnb|UzPDF4NkWwOS=>
H526 NEHCPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknaTWM2OD1{MT62OEBvVQ>? MUWyOFE3PjVyNR?=
N592 MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF2LkGyJI5O MmO2NlQyPjZ3MEW=
H620 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\IWpNYUUN3ME2zNk43PyCwTR?= MX6yOFE3PjVyNR?=
H792 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3rVpQ1UUN3ME20OU4xPyCwTR?= NHHMeXgzPDF4NkWwOS=>
H1173 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTsTWM2OD1zMj62NkBvVQ>? MnjwNlQyPjZ3MEW=
AC3 NXjEVHB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13pe2lEPTB;MkWuPUBvVQ>? MWGyOFE3PjVyNR?=
H82 NWLjPVVMTnWwY4Tpc44hSXO|YYm= MXKzNEBvVQ>? Mk\GO|IhcA>? M4D5N4lv\HWlZYOgdIVze2m|dHXueEBIOi:PIIDoZZNmKGG{cnXzeC=> M37DW|I1OTZ4NUC1
GLC4 M1\tV2Z2dmO2aX;uJGF{e2G7 NHu4dGE{OCCwTR?= NYnWcm82PzJiaB?= Ml3pbY5lfWOnczDw[ZJ{cXO2ZX70JGczN01icHjhd4Uh[XK{ZYP0 MmjQNlQyPjZ3MEW=
H146  M{HvWWZ2dmO2aX;uJGF{e2G7 NIDhSI0{OCCwTR?= NELheHo4OiCq NUPk[5NscW6mdXPld{Bx\XK|aYP0[Y51KEd{L12gdIhie2ViYYLy[ZN1 MmXCNlQyPjZ3MEW=
OVCAR-5 Ml\vR4VtdCCYaXHibYxqfHliQYPzZZk> NGDzfVUxNTFyMECgcm0> M2q0SFczKGh? M2HsR4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MYOyN|kxODF|Nh?=
OVCAR-8 NHzQeVJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4DIcVAuOTByMDDuUS=> NGTVcZM4OiCq M{nXc4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFvmVYwzOzlyMEGzOi=>
A1847 NFH2dJdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NInC[W8xNTFyMECgcm0> M1e1UFczKGh? M{jPSIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHniNmszOzlyMEGzOi=>
SKOV-3 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3uzUlAuOTByMDDuUS=> Mn3HO|IhcA>? MkfPbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NGO3VmgzOzlyMEGzOi=>
OVCAR-5 Mo\NRZBweHSxc3nzJGF{e2G7 MYSxNE0yODBibl2= MWeyOE81QC95MjDo MlfybY5lfWOnczDhdI9xfG:|aYOgeIlu\SCjbnSg[I9{\SCmZYDlcoRmdnSueR?= NGfqUXkzOzlyMEGzOi=>
OVCAR-8 MkHyRZBweHSxc3nzJGF{e2G7 MoLZNVAuOTByIH7N M{TMSlI1NzR6L{eyJIg> NX;iToN1cW6mdXPld{BieG:ydH;zbZMhfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboTsfS=> MVGyN|kxODF|Nh?=
A1847 NU\tO4xPSXCxcITvd4l{KEG|c3H5 M1;aTVExNTFyMDDuUS=> NIfaSWwzPC92OD:3NkBp NHv2NoJqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nIHHu[EBld3OnIHTldIVv\GWwdHz5 NYKycZFbOjN7MECxN|Y>
H2228 NIDHdmFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYDGdo5IOC1zMECwJI5O MofZO|IhcA>? MYnJR|UxRTF|IH7N M1rNZVI{PTN|Mk[1
H3122 MnO0R4VtdCCYaXHibYxqfHliQYPzZZk> MkC2NE0yODByIH7N MUS3NkBp MXXJR|UxRTFyIH7N MoDPNlM2OzN{NkW=
K008 MkfCR4VtdCCYaXHibYxqfHliQYPzZZk> NYHkNGUyUUN3ME22NEBvVQ>? MnXjNlM1OTh3MkO=
K028 MkXTR4VtdCCYaXHibYxqfHliQYPzZZk> NV3tfIF6UUN3ME24OEBvVQ>? NHG3eIQzOzRzOEWyNy=>
K029 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NULrblR6UUN3ME20OkBvVQ>? NGrPWpMzOzRzOEWyNy=>
M23 M2PMeWNmdGxiVnnhZoltcXS7IFHzd4F6 M2rkUGlEPTB;M{euOUBvVQ>? NYjNZ4YzOjN2MUi1NlM>
K033 NI\iU3dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV7JR|UxRTd3LkWgcm0> NUTyT|dlOjN2MUi1NlM>
K008 MYrGeY5kfGmxbjDBd5NigQ>? MX6yOVAhdk1? NFzUUlkzPCCq MlzMbY5lfWOnczDHNkBienKnc4S= MkLMNlM1OTh3MkO=
K028 M2C0SWZ2dmO2aX;uJGF{e2G7 M4K3NFI2OCCwTR?= NGnXVHozPCCq NVniO3gycW6mdXPld{BIOiCjcoLld5Q> NFPzV5ozOzRzOEWyNy=>
K029 NFeyPFZHfW6ldHnvckBCe3OjeR?= NHPrZ5czPTBibl2= NFu2OGczPCCq MWDpcoR2[2W|IFexJIFzemW|dB?= NX7jUJJTOjN2MUi1NlM>
M23 MX3GeY5kfGmxbjDBd5NigQ>? NYXNWFliOjVyIH7N NIDhN5QzPCCq NEnofG1qdmS3Y3XzJGcyKGGwZDDHNk9OKGG{cnXzeC=> MXOyN|QyQDV{Mx?=
K033 M1TTemZ2dmO2aX;uJGF{e2G7 M3\OelI2OCCwTR?= M3W4c|I1KGh? MUfpcoR2[2W|IHGgcY9l\XO2IHnuZ5Jm[XOnIHnuJGcyKHCxcIXsZZRqd25? NYnZd2ZROjN2MUi1NlM>
K008 NFX1W3VCeG:ydH;zbZMhSXO|YYm= NXPsTWxGOTByIH7N NEDqTJA4OiCq NGDmbnN{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| NEHoVYUzOzRzOEWyNy=>
K028 NXe1OJBkSXCxcITvd4l{KEG|c3H5 NEK2SZkyODBibl2= MUW3NkBp NEnZSoV{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| MoHjNlM1OTh3MkO=
K029 NXO1O3dESXCxcITvd4l{KEG|c3H5 MVmxNFAhdk1? NGfwbIU4OiCq NIXoZZV{cWewaX\pZ4FvfGy7IHnu[JVk\XNiYYDvdJRwe2m| Mn7HNlM1OTh3MkO=
M23 MV;BdI9xfG:|aYOgRZN{[Xl? NI\YeoEyODBibl2= M2e2TVczKGh? NV;SR|NNe2mpbnnmbYNidnSueTDpcoR2[2W|IHHwc5B1d3Orcx?= MYWyN|QyQDV{Mx?=
K033 M4jZe2Fxd3C2b4Ppd{BCe3OjeR?= NF;UUZcyODBibl2= M3HKdlczKGh? M3jUU5Nq\26rZnnjZY51dHliaX7keYNmeyCjcH;weI9{cXN? NYT3XYI6OjN2MUi1NlM>
RD NHXRNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRThibl2= M3;CcFI{OzB|N{Sx
Rh41 NF30TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzyd3dIUUN3ME2xNE41KG6P MlXXNlM{ODN5NEG=
Rh18 NGrZXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD14LkKgcm0> M3f1XFI{OzB|N{Sx
Rh30 M{fpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[3PGlEPTB;NT62JI5O MVOyN|MxOzd2MR?=
BT-12 NWTsPIZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O0SWlEPTB;MUSuN{BvVQ>? MWeyN|MxOzd2MR?=
CHLA-266 NFyxRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fQT2lEPTB;MkeuNUBvVQ>? NVT4VpU{OjN|MEO3OFE>
TC-71 NHPiW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTRwNTDuUS=> M2[zW|I{OzB|N{Sx
CHLA-9 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C0WmlEPTB;ND62JI5O NWi3RXJ1OjN|MEO3OFE>
CHLA-10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LkPWlEPTB;NT63JI5O NIS0ZZIzOzNyM{e0NS=>
CHLA-258 NULZcYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTCXY9KSzVyPU[uOEBvVQ>? MlPaNlM{ODN5NEG=
SJ-GBM2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLQVlNKSzVyPUGyMlkhdk1? NFH5NlYzOzNyM{e0NS=>
NB-1643 NGXPfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2mw[2lEPTB;Nz60JI5O M3jMUlI{OzB|N{Sx
NB-EBc1 M1ruTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjYTWM2OD1zNj64JI5O MWKyN|MxOzd2MR?=
CHLA-90 NGH2fFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTDTWM2OD1{Mj6zJI5O MlTzNlM{ODN5NEG=
CHLA-136 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH6cWVKSzVyPUKzMlIhdk1? MYqyN|MxOzd2MR?=
NALM-6 M2XLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHOSG5KSzVyPUGxMlchdk1? MkK2NlM{ODN5NEG=
COG-LL-317 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTRwNDDuUS=> MnPYNlM{ODN5NEG=
RS4;11 NXK4V3JzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF|LkWgcm0> Mnr6NlM{ODN5NEG=
MOLT-4 NFrTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fhN2lEPTB;MUCuOkBvVQ>? NYPiRotQOjN|MEO3OFE>
CCRF-CEM (1) NEXSUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M330NWlEPTB;MUKuOUBvVQ>? MoHJNlM{ODN5NEG=
CCRF-CEM (2) MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq5TWM2OD15LkKgcm0> NX;rdGtuOjN|MEO3OFE>
Kasumi-1 M3vpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PyfGlEPTB;NT64JI5O NFSyXJIzOzNyM{e0NS=>
Karpas-299 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LpXGlEPTB;OT62JI5O MXSyN|MxOzd2MR?=
Ramos-RA1 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjpS4VKUUN3ME23MlQhdk1? NWGwUYFVOjN|MEO3OFE>
LNCaP MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDiNmxpUUN3ME24JI5O MlTGNlMyPTJyMES=
VCaP MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH60Zm9KSzVyPUegcm0> NY\TS2JROjNzNUKwNFQ>
H1355 M4rRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPYbFFKUUN3ME21JI5O M1i1PFI{ODF{MkS4
H157 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jjZmlEPTB;NzDuUS=> M1zac|I{ODF{MkS4
H460 M2TIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrpcmpHUUN3ME24JI5O NH;XO2czOzBzMkK0PC=>
IA-LM M3TVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfOe|NMUUN3ME2xNEBvVQ>? M2f3PVI{ODF{MkS4
HOP-62 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XIO2lEPTB;MUGgcm0> M4\MbVI{ODF{MkS4
H23 M3z3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nMfmlEPTB;MUGgcm0> NGXlepkzOzBzMkK0PC=>
H2030 NWHrUoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvEZ2VKSzVyPUGyJI5O M3TOT|I{ODF{MkS4
H441 M3e1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjVe5lzUUN3ME2xOEBvVQ>? M2jZUFI{ODF{MkS4
H2212 NGjRZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S1[mlEPTB;MUegcm0> NWi1cJVtOjNyMUKyOFg>
SK-LU-1 M4PPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrXGtUUUN3ME2xPEBvVQ>? M4izclI{ODF{MkS4
H2009 NETMelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHGe2cxUUN3ME2xPUBvVQ>? NVzMeG17OjNyMUKyOFg>
H1792 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTjTWM2OD1{MDDuUS=> MkLYNlMxOTJ{NEi=
COR-L23 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rhOWlEPTB;MkKgcm0> NYrzU41SOjNyMUKyOFg>
H727 NGX4b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HzeWlEPTB;Mkigcm0> NES2cogzOzBzMkK0PC=>
H1734 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJ6IH7N MX2yN|AyOjJ2OB?=
H358 NF\QOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrZRYVLUUN3ME2yPUBvVQ>? MYGyN|AyOjJ2OB?=
A549 NXGwU3BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTR|IH7N Ml;KNlMxOTJ{NEi=
H2122 NVXhSlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTV|IH7N NWXJdJhnOjNyMUKyOFg>
Calu-1 NXi1UWdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rWSGlEPTB;NUigcm0> NUe3ZnA5OjNyMUKyOFg>
Calu-6 NWDK[2xbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZ2IH7N NHO4[YkzOzBzMkK0PC=>
NCI-H1975 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3niOVQ5KGh? Mle5TWM2OD1zNjDuUS=> NEW5[m0zOjF2NE[2OS=>
NCI-H1975 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp NIq4R5RKSzVyPUigcm0> M1ewZlIzOTR2Nk[1

... Click to View More Cell Line Experimental Data

In vivo Administration of Ganetespib leads to significant tumor shrinkage in several tumor xenograft models in mice and appears to be less toxic. Furthermore Ganetespib demonstrated better tumor penetration compared with tanespimycin.[2] Ganetespib inhibits in vivo tumor growth in both malignant mast cell and OSA xenograft models. Ganetespib significantly inhibits tumor growth when dosed with two repeating cycles of 25 mg/kg/day for 3 days, with a %T/C value of 18. Ganetespib is well-tolerated, with the vehicle and Ganetespib groups having average bodyweight changes relative to the start of the study of +0.3% and -8.1% on day 17, respectively.[4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OSA cells
  • Concentrations: 0.001-1μM
  • Incubation Time: 5 days
  • Method: A total of 1.5 × 103 OSA cells are seeded in 96-well plates in 10% serum-containing complete medium and incubated overnight to determine the 50% inhibitory concentrations. Plates are, harvested at day 5 following 0.001, 0.005, 0.01, 0.05, 0.1, 0.5 and 1 μM Ganetespib, treatment and analyzed. Fluorescence measurements are made using a plate reader with excitation at 485 nm and emission detection at 530 nm. Relative cell number is calculated as a percentage of the control wells: absorbance of sample/absorbance of DMSO treated cells × 100.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Female severe combined immune-deficient (SCID) mice
  • Formulation: In DMSO and diluted 1:10 with 20% Cremophor RH 40
  • Dosages: 25 mg/kg/day for 3 days
  • Administration: Tail vein injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 40 mg/mL (109.76 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 364.4
Formula

C20H20N4O3

CAS No. 888216-25-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01962948 Active not recruiting Recurrent Fallopian Tube Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Primary Peritoneal Cavity Cancer Fox Chase Cancer Center|National Cancer Institute (NCI) October 9 2013 Phase 1|Phase 2
NCT02012192 Terminated Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Medical University Innsbruck|European Commission July 4 2014 Phase 1|Phase 2
NCT01173523 Completed Small Cell Lung Cancer David M. Jackman MD|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Synta Pharmaceuticals Corp.|Dana-Farber Cancer Institute July 28 2010 Phase 2
NCT02637375 Withdrawn Breast Cancer University of Chicago May 2016 Not Applicable
NCT02334319 Terminated Stage I Hypopharyngeal Squamous Cell Carcinoma|Stage I Laryngeal Squamous Cell Carcinoma|Stage I Oral Cavity Squamous Cell Carcinoma|Stage I Oropharyngeal Squamous Cell Carcinoma|Stage II Hypopharyngeal Squamous Cell Carcinoma|Stage II Laryngeal Squamous Cell Carcinoma|Stage II Oral Cavity Squamous Cell Carcinoma|Stage II Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Squamous Cell Carcinoma|Stage III Laryngeal Squamous Cell Carcinoma|Stage III Oral Cavity Squamous Cell Carcinoma|Stage III Oropharyngeal Squamous Cell Carcinoma|Stage IVA Hypopharyngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Oral Cavity Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma Emory University|Synta Pharmaceuticals Corp. December 2014 Phase 1
NCT02261805 Terminated Cancer|Small Cell Lung Cancer Georgetown University|Synta Pharmaceuticals Corp. October 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does this inhibitor inhibit both isoforms of HSP90?

  • Answer:

    We don't have the information now and it is not very clear in the literature either. From following two references, it indicates that Ganetespib might be specific to the alpha form “Ganetespib binds to the ATP binding site of Hsp90 alpha with a Kd of 110 nM” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477583/

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products4

Tags: buy Ganetespib (STA-9090) | Ganetespib (STA-9090) supplier | purchase Ganetespib (STA-9090) | Ganetespib (STA-9090) cost | Ganetespib (STA-9090) manufacturer | order Ganetespib (STA-9090) | Ganetespib (STA-9090) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID